News | Latest Breaking News Stories & Headlines

Biogen has lifted its full-year profit forecast due to cost cuts and better-than-expected sales of its various treatments

Biogen lifts 2024 profit forecast on cost cuts, new drugs

Biogen has today lifted its full-year profit forecast due to cost cuts and better-than-expected sales of its various treatments, even as the US adoption of its Alzheimer's drug remains slow.

Business • 01 Aug 24

Biogen said it expects full-year adjusted profit per share in the range of $14.50 to $15 compared with $15 to $16 forecast previously

Biogen cuts profit view on higher M&A costs

Biogen has today cut its annual profit forecast, which slipped below Wall Street expectations, due to higher costs from its recent buyout of Reata Pharmaceuticals and the launch of its Alzheimer's treatment Leqembi.

Business • 08 Nov 23

Biogen and Eisai said their experimental drug slowed progress of the brain-wasting disease by 27% compared with a placebo

Biogen and Eisai stocks soar on Alzheimer's success

Shares in Biogen and Eisai soared today reflecting the surprise trial success of their experimental Alzheimer's drug, which also lifted the stocks of rival drugmakers Roche and Eli Lilly.

Business • 28 Sep 22

The vote is a possible blow to the prospects of Biogen drug already grappling with a slow rollout in the US

Biogen's Alzheimer's drug gets negative European vote

A European regulatory panel voted against approval of Biogen's Alzheimer's disease drug, in a possible blow to the prospects of the drug already grappling with a slow rollout in the US.

Business • 17 Nov 21

The judicial review relates to the second largest tax assessment in the history of the State

Perrigo action over disputed €1.64bn tax bill adjourned

A judicial review of a decision by Revenue to issue pharmaceutical company Perrigo with a tax bill for €1.64bn will not now formally begin until tomorrow.

Business • 03 Jun 20